Alnylam Pharmaceuticals, Inc.

BMV:ALNY * Stock Report

Market Cap: Mex$713.2b

Alnylam Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BMV:ALNY * Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Apr 25SellMex$167,516Colleen ReitanIndividual36Mex$4,653.22
03 Mar 25SellMex$6,299,072Jeffrey PoultonIndividual1,264Mex$5,077.02
03 Mar 25SellMex$3,687,809Kevin FitzgeraldIndividual740Mex$5,077.02
03 Mar 25SellMex$3,867,319Pushkal GargIndividual776Mex$5,077.02
03 Mar 25SellMex$2,347,182Tolga TangulerIndividual471Mex$5,056.38
03 Mar 25SellMex$19,321,250Yvonne GreenstreetIndividual3,877Mex$5,077.02
28 Feb 25SellMex$2,461,333Kevin FitzgeraldIndividual496Mex$5,012.07
14 Feb 25SellMex$3,437,320Kevin FitzgeraldIndividual663Mex$5,380.73
14 Feb 25SellMex$8,091,810Pushkal GargIndividual1,561Mex$5,380.73
14 Feb 25SellMex$5,012,623Jeffrey PoultonIndividual967Mex$5,380.73
14 Feb 25SellMex$6,287,909Yvonne GreenstreetIndividual1,213Mex$5,380.73
26 Nov 24SellMex$7,640,867Kevin FitzgeraldIndividual1,469Mex$5,228.19
26 Nov 24SellMex$8,748,772Jeffrey PoultonIndividual1,682Mex$5,228.19
26 Nov 24SellMex$7,640,867Tolga TangulerIndividual1,469Mex$5,228.19
26 Nov 24SellMex$8,748,772Pushkal GargIndividual1,682Mex$5,228.19
26 Nov 24SellMex$27,146,174Yvonne GreenstreetIndividual5,219Mex$5,228.19
17 Oct 24BuyMex$205,568Colleen ReitanIndividual36Mex$6,004.16
25 Jun 24SellMex$6,719,754Jeffrey PoultonIndividual1,605Mex$4,262.80
25 Jun 24SellMex$8,804,594Pushkal GargIndividual2,103Mex$4,262.80
25 Jun 24SellMex$5,015,717Kevin FitzgeraldIndividual1,198Mex$4,262.80
25 Jun 24SellMex$6,719,754Tolga TangulerIndividual1,605Mex$4,262.80
25 Jun 24SellMex$34,754,044Yvonne GreenstreetIndividual8,301Mex$4,262.80

Insider Trading Volume

Insider Buying: ALNY * insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALNY *?
Owner TypeNumber of SharesOwnership Percentage
State or Government84,6050.0652%
Individual Insiders464,8640.358%
Public Companies4,444,4453.43%
Institutions124,711,51296.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 82.27% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20.3%
Capital Research and Management Company
26,147,703Mex$144.6b16.2%0.32%
11.1%
FMR LLC
14,357,609Mex$79.4b20.7%0.22%
9.8%
The Vanguard Group, Inc.
12,635,096Mex$69.9b1.02%0.05%
7.66%
BlackRock, Inc.
9,885,257Mex$54.7b1.83%0.04%
5.11%
T. Rowe Price Group, Inc.
6,591,087Mex$36.4b-0.76%0.15%
3.84%
Wellington Management Group LLP
4,953,347Mex$27.4b-20.2%0.21%
3.45%
Regeneron Pharmaceuticals, Inc.
4,444,445Mex$24.6b0%no data
3.13%
Baillie Gifford & Co.
4,040,259Mex$22.3b-17.3%0.47%
2.81%
Dodge & Cox
3,622,535Mex$20.0b-4.17%0.32%
2.69%
State Street Global Advisors, Inc.
3,468,315Mex$19.2b-1.88%0.03%
1.78%
Norges Bank Investment Management
2,296,781Mex$12.7b0%0.05%
1.66%
Geode Capital Management, LLC
2,147,203Mex$11.9b3.22%0.04%
1.41%
JP Morgan Asset Management
1,823,933Mex$10.1b10.9%0.05%
1.23%
American Century Investment Management Inc
1,592,733Mex$8.8b17.6%0.2%
0.98%
Orbis Investment Management Limited
1,268,112Mex$7.0b75.9%1.26%
0.75%
Legal & General Investment Management Limited
960,959Mex$5.3b3.74%0.05%
0.67%
UBS Asset Management AG
861,902Mex$4.8b-13.1%0.02%
0.63%
Bellevue Asset Management AG
809,095Mex$4.5b-12%2.63%
0.57%
Northern Trust Global Investments
734,919Mex$4.1b-5.88%0.03%
0.56%
Winslow Capital Management, LLC
726,336Mex$4.0b0%0.87%
0.52%
Pictet Asset Management Limited
664,722Mex$3.7b-12.4%0.13%
0.42%
Invesco Ltd.
544,638Mex$3.0b86.2%0.04%
0.41%
Loomis Sayles & Company, L.P.
525,303Mex$2.9b-7.73%0.17%
0.4%
Charles Schwab Investment Management, Inc.
513,962Mex$2.8b5.46%0.02%
0.38%
Amundi Asset Management SAS
496,301Mex$2.7b-16.4%0.03%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/12 11:20
End of Day Share Price 2024/11/15 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 61 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg